Current Pharmaceutical Biotechnology (CURR PHARM BIOTECHNO)

Publisher: Bentham Science Publishers

Journal description

Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in pharmaceutical biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of pharmaceutical biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.


Journal Impact: 1.61*

*This value is calculated using ResearchGate data and is based on average citation counts from work published in this journal. The data used in the calculation may not be exhaustive.

Journal impact history

2016 Journal impact Available summer 2017
2015 Journal impact 1.61
2014 Journal impact 0.83
2013 Journal impact 1.37
2012 Journal impact 0.69
2011 Journal impact 0.75
2010 Journal impact 1.81
2009 Journal impact 2.47
2008 Journal impact 2.40
2007 Journal impact 3.15
2006 Journal impact 3.25
2005 Journal impact 3.04
2004 Journal impact 2.88
2003 Journal impact 2.57
2002 Journal impact 2.23
2001 Journal impact 0.68

Journal impact over time

Journal impact
Year

Additional details

Cited half-life 3.30
Immediacy index 0.74
Eigenfactor 0.01
Article influence 0.90
Website Current Pharmaceutical Biotechnology website
Other titles Current pharmaceutical biotechnology (Online)
ISSN 1389-2010
OCLC 55201370
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

This journal may support self-archiving.
Learn more

Publications in this journal

  • [Show abstract] [Hide abstract] ABSTRACT: Toxicity assessment is an important tool in drug discovery and development. PT-31 (3-(2-chloro-6-fluorobenzyl)-imidazolidine-2,4-dione) is an imidazolidine-2,4-dione analogue of clonidine that displays a dose-dependent analgesic profile and synergism with morphine. This study investigated genotoxic and mutagenic effects of PT-31 in Swiss mice. For this ten mice (M1:F1) per group were treated with PT-31 intraperitoneally (i.p.) at 0.5, 1.0 and 5.0 mg/kg. The DMSO (0.5%) and 50 mg/kg cyclophosphamide ( i.p.) were taken as negative (NC) and positive controls, respectively. The bone marrow cells were collected after 24 h, while peripheral blood was collected after 30 min, 12 h and 24 h of the treatment for the comet assay. Micronucleus (MN) test was performed only on bone marrow cells collected after 24 h of i.p. treated animals. A hundred cells were considered for the comet assay and quantification of the index of damage and frequency of damage. Lack of genotoxicity with 0.5 mg/kg of PT-31 and DNA repair ability with 0.5 and 1.0 mg/kg doses at 12 h and 24 h in comparison to NC group was observed (P<0.05). There was an increase in MN formation by PT-31 1.0 mg/kg and 5.0 mg/kg treated female and male mice, respectively. PT-31 induced genotoxic and mutagenic effects only in higher doses.
    Article · Aug 2016 · Current Pharmaceutical Biotechnology
  • [Show abstract] [Hide abstract] ABSTRACT: Fetal or intrauterine growth restriction (FGR or IUGR) is a concerning health issue due to its implications in mortality and morbidity of neonates but also because of its long-term consequences on health and disease risk of the individuals. Its main cause is an insufficient supply of nutrients and oxygen by maternal (malnutrition or hypobaric hypoxia) or placental factors (placental insufficiency) during late gestation, when the requirements of fetus are higher. The availability of reliable animal models would be highly useful for the future development of diagnostic, preventive and therapeutic strategies. Most of the studies using animal models have been performed in rodents, whilst the use of large animals (sheep and swine) is scarce. The objective of the current review is to offer an overview on the possibilities of large animals for translational research in IUGR related to inadequate maternal conditions and/or placental dysfunction.
    Article · May 2016 · Current Pharmaceutical Biotechnology
  • [Show abstract] [Hide abstract] ABSTRACT: This work aimed to characterize and evaluate the antihypertensive effect of the (-)-β-pinene/β-cyclodextrin (βP/β-CD) complex. The complex was prepared through physical mixture and slurry complexation methods and was analyzed through differential scanning calorimetry, thermogravimetry/derivative thermogravimetry, fourier transform infrared spectroscopy, diffraction X-ray, docking and scanning electron microscopy. Normotensive or L-NAME-induced hypertensive rats were used in pharmacological experiments. Mean arterial pressure (MAP) was determined with direct blood pressure measurements from the abdominal aorta. The drugs were orally administrated and their effects were recorded during 48 hours. Vascular effects of βP were evaluated in isolated ring of mesenteric artery. The physicochemical characterization showed βP/β-CD complex formation. In hypertensive rats (MAP = 156 ± 16 mmHg), the complex, but not βP alone, promoted hypotension at 36 and 48 hours after administration (MAP = 124 ± 3 and 110 ± 5 mmHg, respectively). In arterial rings, βP vasorelaxed rings precontracted with phenylephrine (Emax = 105 ± 6%), which was not changed after the removal of the vascular endothelium (Emax = 108 ± 4%), after the pre-contraction with KCl 80 mM (Emax = 107 ± 8%) or S(-)-BayK8644 (Emax = 107 ± 5%), or after incubation with TEA (Emax = 113 ± 4%). Finally, βP inhibited CaCl2- and sodium-orthovanadate-induced contractions. In conclusion, the slurry complexation method was the best among them. Pharmacological results demonstrated that the complex promoted antihypertensive effect. Furthermore, βP induced endothelium-independent vasorelaxation possibly caused by the inhibition of the Ca2+ influx through L-type Ca2+ channel associated to a decrease in calcium sensitivity.
    Article · Apr 2016 · Current Pharmaceutical Biotechnology
  • Article · Nov 2015 · Current Pharmaceutical Biotechnology
  • [Show abstract] [Hide abstract] ABSTRACT: MicroRNAs, whose transcription is regulated by members of the tumor protein p53 family, modulate the expression of numerous metabolic enzymes, significantly altering tumor cell response to chemotherapeutic treatments. The role for ΔNp63α-regulated microRNAs in regulation of cell cycle arrest, apoptosis and autophagy in squamous cell carcinoma (SCC) cells upon cisplatin exposure has been reported. The current study indicated that the selected microRNA targets differentially regulated by ΔNp63α in cisplatin-sensitive and cisplatin-resistant SCC cells could alter the expression of a few metabolic enzymes, thereby potentially contributing to the metabolic changes in SCC cells upon cisplatin exposure. Finally, the modulation of specific targets (e.g., SREBF2, AKT2, G6PD, CPS1, FADS1, and ETNK1) using a combination of microRNA mimics and siRNA silencing has shown that a suppression of these metabolic factors/ enzymes could confer a sensitivity of SCC cells to cisplatin. Thus, the Δ Np63α-regulated microRNAs were found to regulate the levels of several metabolic factors and enzymes, thereby potentially contributing to the response of larynx and tongue-derived SCC cells to platinum chemotherapy.
    Article · Sep 2015 · Current Pharmaceutical Biotechnology
  • Article · Sep 2015 · Current Pharmaceutical Biotechnology
  • [Show abstract] [Hide abstract] ABSTRACT: In translational medicine, the discovery of new drugs or new potential uses for currently available drugs is crucial for treating the resistant hypertension associated with renal artery stenosis. The phosphodiesterase 5 inhibitor sildenafil has been shown to reduce blood pressure and to improve the endothelium-dependent relaxation in the two kidney, one clip (2K1C) mouse model of renovascular hypertension. In the present study, we evaluated the effects of sildenafil (40 mg/kg/day for two weeks) on the endothelial structure and contractile function in mesenteric resistance arteries 28 days after clipping the renal artery. The data showed an enhanced vascular contractile response to norepinephrine in 2K1C hypertensive mice (56%) when compared with Sham mice, which was associated with increased oxidative stress and with a thinning of endothelial cells. Sildenafil treatment caused a significant amelioration in the enhanced contractile responsiveness (18%), which was associated to the recovery of the endothelial surface and abolishment of the oxidative stress. These data suggest that sildenafil could be considered a promising therapeutic option to manage endothelial dysfunction and hypertension in resistant patients.
    Article · Sep 2015 · Current Pharmaceutical Biotechnology
  • Article · Aug 2015 · Current Pharmaceutical Biotechnology